• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Erasca Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/13/25 4:10:10 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ERAS alert in real time by email
    8-K
    0001761918false00017619182025-05-132025-05-13

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 13, 2025

     

     

    Erasca, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40602

    83-1217027

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    3115 Merryfield Row

    Suite 300

     

    San Diego, California

     

    92121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (858) 465-6511

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.0001 par value per share

     

    ERAS

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 13, 2025, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months ended March 31, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

    In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit Description

    99.1 Press Release Issued May 13, 2025

    104 Cover Page Interactive Data File


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Erasca, Inc.

     

     

     

     

    Date:

    May 13, 2025

    By:

    /s/ Ebun Garner

     

     

     

    Ebun Garner, General Counsel

     


    Get the next $ERAS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ERAS

    DatePrice TargetRatingAnalyst
    3/26/2025$5.00Outperform
    Raymond James
    11/18/2024$6.00Buy
    Jefferies
    3/11/2024$8.00Overweight
    CapitalOne
    1/5/2024$11.00 → $6.00Buy → Neutral
    BofA Securities
    10/11/2023$10.00Buy
    H.C. Wainwright
    3/30/2023$9.00Buy
    Mizuho
    2/24/2023$10.00Buy
    Goldman
    2/3/2023$15.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $ERAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Erasca Inc.

      SC 13G/A - Erasca, Inc. (0001761918) (Subject)

      11/14/24 5:13:04 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Erasca Inc.

      SC 13G/A - Erasca, Inc. (0001761918) (Subject)

      11/14/24 4:04:32 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Erasca Inc.

      SC 13G - Erasca, Inc. (0001761918) (Subject)

      11/14/24 1:28:34 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ERAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by General Counsel & Corp. Sec. Garner Ebun

      4 - Erasca, Inc. (0001761918) (Issuer)

      2/18/25 9:00:03 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and CBO Chacko David M. acquired $24,181 worth of shares (15,461 units at $1.56), increasing direct ownership by 1% to 262,187 units (SEC Form 4)

      4 - Erasca, Inc. (0001761918) (Issuer)

      2/5/25 9:24:43 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Morris Shannon

      4 - Erasca, Inc. (0001761918) (Issuer)

      2/5/25 9:20:22 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ERAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ERAS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Raymond James initiated coverage on Erasca with a new price target

      Raymond James initiated coverage of Erasca with a rating of Outperform and set a new price target of $5.00

      3/26/25 7:49:37 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Erasca with a new price target

      Jefferies initiated coverage of Erasca with a rating of Buy and set a new price target of $6.00

      11/18/24 7:43:18 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CapitalOne initiated coverage on Erasca with a new price target

      CapitalOne initiated coverage of Erasca with a rating of Overweight and set a new price target of $8.00

      3/11/24 7:50:07 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Erasca Reports First Quarter 2025 Business Updates and Financial Results

      Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $411 million as of March 31, 2025 with cash runway guidance extended to H2 2028 SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended M

      5/13/25 4:05:00 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

      IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful extension of cash runway guidance from H2 2027 to H2 2028 following strategic decision to pursue partnership opportunities for naporafenib SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Admini

      5/13/25 8:00:00 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Erasca to Present at the Bank of America Securities Health Care Conference

      SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2025 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will present on Wednesday, May 14, 2025, at 2:35 pm Pacific Time and will also participate in one-on-one investor meetings. A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at E

      5/7/25 8:00:00 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ERAS
    Leadership Updates

    Live Leadership Updates

    See more
    • Erasca Appoints Jean Liu to its Board of Directors

      SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Jean Liu to its board of directors and to its audit committee. Ms. Liu brings over 20 years of professional experience advising biopharmaceutical companies on corporate, intellectual property, compliance, and general legal matters. "Jean Liu has been a seasoned executive with Seagen during its transformation into a leading global, multiproduct oncology company, and she also is one of the most strategic busine

      4/27/22 8:00:00 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Erasca Strengthens Leadership Team with Two Key Executive Appointments

      Lisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Lisa Tesvich-Bonora as Chief People Officer and the promotion of Robert Shoemaker to Senior Vice President of Research. "I am thrilled to welcome Lisa to the Erasca family. With over two decades of experience in creating collaborative and engaging environments where employees can thrive, she bring

      1/18/22 8:00:00 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ERAS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Casdin Alexander W. bought $181,920 worth of shares (80,000 units at $2.27) (SEC Form 4)

      4 - Erasca, Inc. (0001761918) (Issuer)

      5/22/24 6:57:45 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Start Valerie Denise Harding bought $18,480 worth of shares (10,000 units at $1.85) (SEC Form 4)

      4 - Erasca, Inc. (0001761918) (Issuer)

      12/8/23 9:10:12 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lim Jonathan E bought $1,696,179 worth of shares (1,000,000 units at $1.70) (SEC Form 4)

      4 - Erasca, Inc. (0001761918) (Issuer)

      12/6/23 7:41:47 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ERAS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Erasca Inc.

      10-Q - Erasca, Inc. (0001761918) (Filer)

      5/13/25 4:24:15 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Erasca Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Erasca, Inc. (0001761918) (Filer)

      5/13/25 4:10:10 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Erasca Inc.

      DEFA14A - Erasca, Inc. (0001761918) (Filer)

      4/29/25 4:28:47 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ERAS
    Financials

    Live finance-specific insights

    See more
    • Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

      Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today anno

      5/16/24 8:02:00 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Erasca Reports First Quarter 2024 Business Updates and Financial Results

      Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026 SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March

      5/8/24 4:01:00 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

      Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial Robust balance sheet with cash, cash equivalents, and marketable securities of $322 million as of December 31, 2023 Erasca to host R&D update conference call and webcast Thursday, March 28, 2024 at 8:30 am ET SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and comm

      3/27/24 4:01:00 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care